TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascelia Pharma AB ( (SE:ACE) ) just unveiled an announcement.
Ascelia Pharma has filed a new patent application for Orviglance, an innovative liver imaging drug designed to enhance the detection of liver lesions in patients with reduced kidney function. This patent aims to extend market protection for Orviglance until 2046, potentially boosting its commercial value and strengthening Ascelia Pharma’s position in the market.
More about Ascelia Pharma AB
Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs to address unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm. It has two drug candidates, Orviglance and Oncoral, in development.
YTD Price Performance: 2.91%
Average Trading Volume: 1,538,379
Technical Sentiment Signal: Sell
Current Market Cap: SEK381.1M
See more data about ACE stock on TipRanks’ Stock Analysis page.